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Baclofen-induced Changes in the Resting Brain Modulate Smoking 
Cue Reactivity: A Double-blind Placebo-controlled Functional 
Magnetic Resonance Imaging Study in Cigarette Smokers
Ariel Ketcherside1, Kanchana Jagannathan1, Sudipto Dolui1, Nathan Hager1,2, Nathaniel Spilka1, Chaela Nutor1, 
Hengyi Rao1, Teresa Franklin1,*, Reagan Wetherill1,*
1The Center for Studies of Addiction, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2Department of Psychology, 
Old Dominion University, Norfolk, VA, USA
Objective: Smoking cue-(SC) elicited craving can lead to relapse in SC-vulnerable individuals. Thus, identifying treat-
ments that target SC-elicited craving is a top research priority. Reduced drug cue neural activity is associated with 
recovery and is marked by a profile of greater tonic (resting) activation in executive control regions, and increased 
connectivity between executive and salience regions. Evidence suggests the GABA-B agonist baclofen can reduce drug 
cue-elicited neural activity, potentially through its actions on the resting brain. Based on the literature, we hypothesize 
that baclofen’s effects in the resting brain can predict its effects during SC exposure.
Methods: In this longitudinal, double blind, placebo-controlled neuropharmacological study 43 non-abstinent, sated 
treatment-seeking cigarette smokers (63% male) participated in an fMRI resting-state scan and a SC-reactivity task prior 
to (T1) and 3 weeks following randomization (T2; baclofen: 80 mg/day; n = 21). Subjective craving reports were ac-
quired before and after SC exposure to explicitly examine SC-induced craving.
Results: Whole-brain full-factorial analysis revealed a group-by-time interaction with greater resting brain activation of 
the right dorsolateral prefrontal cortex (dlPFC) at T2 in the baclofen group (BAC) (p FWEcorr = 0.02), which was associated 
with reduced neural responses to SCs in key cue-reactive brain regions; the anterior ventral insula and ventromedial 
prefrontal cortex (p FWEcorr ＜ 0.01). BAC, but not the placebo group reported decreased SC-elicited craving (p = 0.02). 
Conclusion: Results suggest that baclofen mitigates the reward response to SCs through an increase in tonic activation 
of the dlPFC, an executive control region. Through these mechanisms, baclofen may offer SC-vulnerable smokers pro-
tection from SC-induced relapse.
KEY WORDS: Baclofen; Cerebral blood flow; Cue-elicited craving; Nicotine; Perfusion fMRI; Resting-state.
INTRODUCTION
The consequences of smoking are devastating, yet ap-
proximately 20% of the world’s population above the age 
of 14 continues to smoke [1]. Although smokers indicate 
that they want to quit, success rates are low [2], and over 
half of those who have made a quit attempt will relapse 
within a year [3]. Because of the myriad caveats asso-
ciated with the study of real-world smoking, the role of 
smoking cue (SC) exposure in relapse remains equivocal 
[4]. However, SC-elicited craving persists as a key metric 
by which to assess the severity of nicotine use disorder be-
cause cues elicit conditioned responses such as craving 
and approach behavior [5-7]. Further, former smokers 
continue to view SCs as salient long after cessation, and 
often cite SC exposure as their reason for relapse [8]. 
SCs increase neural activity in reward-related brain re-
gions, independent of pharmacological withdrawal [9], 
SC-induced craving can predict increased smoking be-
havior [10], and SC-elicited neural activation in reward 
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regions can predict relapse [11]. Furthermore, decreased 
functional connectivity between a salience region (anterior 
ventral insula; avInsula) and an executive control region 
(the dorsolateral prefrontal cortex; dlPFC) during SC ex-
posure predicts relapse, indicating that decoupling of sali-
ence and executive control regions contribute to SC vul-
nerability [12]. Similarly, smokers with greater response 
in reward regions during SC exposure have greater diffi-
culty quitting smoking [13]. Collectively, these studies 
elucidate a select role of SC vulnerability in relapse. 
The primary smoking cessation medications are nic-
otine replacement therapy, bupropion, and varenicline, 
all three of which reduce withdrawal from nicotine [14]. 
Varenicline, the most effective and most commonly pre-
scribed, has a second mechanism: before cessation, it 
blocks nicotine’s reinforcing effects [15,16]. Nonetheless, 
varenicline does not help most individuals to whom it is 
prescribed, as relapse rates remain high [17]. In line with 
varenicline’s mechanism, varenicline-responders could 
represent a subgroup of smokers whose vulnerability to 
relapse is coupled with nicotine reinforcement, while 
those who do not respond to varenicline may have unmet 
vulnerabilities such as those associated with SC exposure. 
Currently, there are no medications directly targeting SC 
reactivity to aid SC-vulnerable individuals.
GABA-B agonists inhibit dopaminergic afferents in re-
ward regions, including nicotine-induced reward signal-
ing [18]. There is substantial evidence that the GABA-B 
agonist baclofen blocks conditioned drug-related behav-
iors and may target drug cue vulnerabilities in humans 
[19-22]. One functional magnetic resonance imaging (fMRI) 
study showed that baclofen reduced reward-related neural 
responses to cocaine cues in abstinent, treatment-seeking 
cocaine participants, however baclofen-induced changes 
from baseline could not be determined from that study 
[23]. Another recent neuropharmacological study exam-
ined baclofen’s effects on alcohol cue reactivity in ab-
stinent alcohol use disorder (AUD) treatment-seeking pa-
tients relapse [24]. Authors examined cue reactivity prior 
to and after two weeks of medication. Baclofen increased 
activity of the anterior cingulate cortex (ACC) and bi-
lateral dlPFC while decreasing responses in the ventral 
striatum (VS) and orbitofrontal and insular cortices. Responses 
in the ACC and insula predicted time to relapse [24]. 
Collectively, these studies suggest a common mechanism 
whereby baclofen blunts the neural response to drug 
cues, which could be a useful/necessary mechanism of 
blunting cue-induced craving in cue-vulnerable sub-
stance use disorder patients. 
Using the quantitative technique of perfusion fMRI, we 
have shown that baclofen increases cerebral blood flow 
(CBF) in executive control regions, including the dlPFC 
and ACC, in the resting brain and blunts CBF in reward re-
gions, suggesting tonic modulation of the brain at rest 
[25]. Greater tonic activation of executive control re-
gions, as operationalized by resting state neuroimaging, 
could be an indicator of nicotine use disorder improve-
ment: greater tonic executive control may be necessary to 
avoid a lapse when encountering SCs [26-28]. 
In the present study, we seek to extend the findings of 
ourselves and others by determining whether baclofen-re-
lated changes in the resting brain are associated with 
SC-reactivity within cigarette smokers. Based on our pre-
vious findings and those of Holla et al. [24], 2018 and 
Janes et al. [12], 2010, described above, we hypothesized 
(1) that baclofen would increase CBF in the bilateral 
dlPFC and the ACC in the resting brain, and (2) that the in-
creases observed in resting CBF would be associated with 
decreases in CBF during SC exposure in our a priori re-
ward regions (i.e., ventromedial prefrontal cortex/medial 
orbitofrontal cortex [vmPFC/mOFC], VS, and avInsula) 
[9,11,12,24,29,30]. 
METHODS
All procedures were conducted at the University of 
Pennsylvania Center for Studies of Addiction. All proce-
dures were approved by the University of Pennsylvania’s 
Institutional review board (IRB No. 817101) and con-
ducted in accordance with the Declaration of Helsinki. 
All participants provided written informed consent. This 
study was pre-registered at ClinicalTrials.gov, with Identifier: 
NCT01821560.
Participants
Participants were treatment-seeking cigarette smokers, 
18−60 years old, who smoked at least 10 cigarettes per 
day (CPD) for the past 6 months. Interested volunteers 
were recruited by flyers, listservs, and word of mouth and 
completed an initial phone screen and, if eligible, an 
in-person consent and screening visit. After providing in-
formed consent, participants completed the Fagerström 
Baclofen’s Effects on Smoking Cue Responses 291
Fig. 1. Study design. Participants underwent a double-blind, placebo-controlled study in which they received 20 mg q.i.d. baclofen or placebo. 
They participated in a functional magnetic resonance imaging (fMRI) session before randomization (T1), and a second session after three weeks of 
treatment (T2). At each session, one of two similarly valanced smoking cue (SC) and non-SC sets was presented in a pseudorandomized fashion to 
control for habituation.
pCASL, pseudo-continuous arterial-spin labeled; MPRAGE, magnetization-prepared rapid gradient echo.
Test for Nicotine Dependence (FTND) [31] and under-
went physical and psychiatric screening. Physical screen-
ing included a blood test to ensure general physical 
health, an EKG, a urine toxicology test to rule out the pres-
ence of psychoactive drugs, and a pregnancy test in 
females. Psychological screening ascertained any current 
severe psychiatric symptoms, or diagnosis of any sub-
stance use disorders (SUDs) other than nicotine (MINI; 
[32]). Participants were excluded for current other SUDs, 
current Axis 1 DSM-IV disorder, an intellectual ability es-
timate score below 80 [33], use of any other smoking ces-
sation strategies, and any MRI contraindications [34]. 
Potential contraindications were reviewed by the study 
physician, and participants were financially compensated 
for participation. Participants were randomized to receive 
either baclofen or placebo after their first MRI scan. The 
study design is illustrated in Figure 1. 
Twenty-three baclofen recipients (BAC) and 22 place-
bo recipients (PBO) completed study procedures. One 
participant was excluded for abnormally large ventricles 
and one participant was excluded for insufficient sig-
nal-to-noise ratio in their resting-state data. 
Subjective craving scores were excluded for two baclo-
fen participants based on an error in assessment admin-
istration. Analyses were completed on the remaining 21 
BAC and 22 PBO, except the SC-elicited craving analyses 
which included 19 BAC and 22 PBO. Participant charac-
teristics are listed in Table 1. 
Medication
Study medication was manufactured and provided by 
Murty Pharmaceuticals, Inc., Lexington, KY, USA. The 
Investigational Drug Service at the University of Pennsyl-
vania maintained and distributed medication in blister 
packs (randomized by medication group and sex). All 
study staff and participants were blinded to the medi-
cation administered. A nurse practitioner met with partic-
ipants weekly to collect used pill packs (compensation 
was provided to encourage adherence), distribute new 
packs, and monitor adverse events and medication adher-
ence/issues. The most common adverse event reported for 
baclofen is drowsiness. Based on pilot data conducted in 
our lab, we were able to accelerate the titration schedule 
used in our previous study [25] without affecting side ef-
fects, including drowsiness. Similarly to Logge et al. [22], 
2019, we used a titration schedule wherein participants 
reached the full dose of 80 mg (20 mg q.i.d.) by day 4 
(Table 2). 
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Table 1. Demographics and smoking characteristics 
Variable Baclofen (n = 21) Placebo (n = 22)
Group comparisons
t or 2 p value
Sex, male 13 (62) 14 (64) 0.01 0.91
Age 38.9 ± 12 40.2 ± 12 −0.47 0.64
IQ 97.4 ± 12.1 103.8 ± 12.4 −1.64 0.11
Race
African American 12 (55) 14 (64) 0.19 0.66
Caucasian 7 (33) 6 (27) 0.19 0.67
Asian 2 (10) 2 (9) ＜ 0.01 0.96
Ethnicity 
Hispanic 1 (0.1) 3 (0.1) ＜ 0.01 1.0
Education 13.3 ± 1.8 14 ± 1.8 −1.06 0.29
Alcohol use
Endorsed use 12 (50) 13 (59.1) 0.02 0.87
Drinks per drinking day, T1a 2.7 ± 2.10 3.1 ± 2.4 0.46 0.65
Cannabis use
Endorsed use 7 (31.8) 8 (36.4) ＜ 0.01 1.0
Days of cannabis use, T1a 5 ± 2.6 4.5 ± 2.4 0.23 0.82
Smoking characteristics
FTND 4.9 ± 1.5 4.9 ± 1.5 0.19 0.85
Pack years 16.6 ± 13.8 15.6 ± 12.6 0.23 0.82
CPD 
T1 14.4 ± 5.7 13.9 ± 4.8 0.35 0.73
T2 12.9 ± 7.5 9.5 ± 4.7 1.72 0.09
Values are presented as number (%) or mean ± standard deviation. 
T1, before treatment; T2, on medication and after 3 weeks of treatment; FTND, Fagerström Test for Nicotine Dependence; CPD, cigarettes per day.
aIn participants who used this substance in the last 30 days, measured by the Timeline Follow Back. There were no differences between groups in 
any demographics or smoking characteristics. 
Table 2. Baclofen titration schedule 
Study day 8:00 AM 12:00 PM 4:00 PM 8:00 PM
Day 1 PBO 10 BAC PBO 10 BAC
Day 2 PBO 10 BAC 10 BAC 10 BAC
Day 3 PBO 20 BAC 20 BAC 20 BAC
Day 4−7 20 BAC 20 BAC 20 BAC 20 BAC
Week 2−7 20 BAC 20 BAC 20 BAC 20 BAC
Week 8 Day 1−2 PBO 20 BAC 20 BAC 20 BAC
Week 8 Day 3−4 PBO 20 BAC PBO 20 BAC
Week 8 Day 5−6 PBO 10 BAC PBO 10 BAC
Week 8 Day 7 PBO PBO PBO PBO
Baclofen (BAC) was titrated up to full dose (week 1) and tapered 
down (week 8) to mitigate adverse effects, including drowsiness. 
Placebo medication (PBO) was used to ensure blinding during the 
titration process.
Study Design 
To determine the effect of baclofen on neural function 
and SC-elicited craving, we used a double-blind, place-
bo-controlled paradigm. At baseline, participants and 
study staff agreed upon a “Quit Date” on which partic-
ipants would attempt to quit smoking. Importantly, this 
occurred after the second scan (Time 2, T2) to mitigate 
any effects of quitting smoking on brain endpoints. 
Participants were instructed to continue smoking as usual 
until their Quit Date. Participants began the medication 
regimen after their first scan (Time 1, T1). After three 
weeks of treatment, participants underwent a second per-
fusion fMRI scan session following the same scan protocol 
(T2). CPD were recorded at both timepoints. Participants 
then returned for their “Quit Week” appointment, at 
which time they received smoking cessation counseling 
and continued treatment for four additional weeks (Fig. 1).
All MRI sessions occurred in the early afternoon, to 
minimize any confounding effects of time of day, or ef-
fects of participants’ daily routines on study results [35]. 
fMRI sessions included a pseudo-continuous arterial-spin 
labeled (pCASL) perfusion fMRI scan at rest and during a 
SC reactivity task. pCASL is an MRI tool providing an ob-
jective measure of neural activity, using magnetically tag-
ged blood as an inherent tracer [36]. Unlike blood oxygen 
level-dependent fMRI, perfusion fMRI is quantitative, pro-
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viding a measure of blood flow measured in milliliters of 
blood/100 g of tissue/minute. This gives perfusion fMRI 
the unique advantage of providing a baseline measure-
ment, and as such, it is ideal for studying the effect of 
pharmacological agents on neural activity [36]. Further-
more, perfusion fMRI is particularly suited for longitudinal 
studies, as it is reliable and replicable for up to seven 
weeks [37]. Finally, the quantitative technique of perfu-
sion fMRI is ideal for measuring states that accrue slowly 
over time, such as craving generated by drug cues. 
Additionally, craving may persist after stimulus exposure, 
often extinguished only by smoking, thus perfusion fMRI 
is well-suited to our model in which stimuli are presented 
over several minutes. 
At both timepoints, participants were non-abstinent to 
minimize potential confounds introduced by withdrawal 
and to minimize differences between groups in smoking 
behavior, both of which might affect neural responses. 
Participants smoked ad libitum throughout the day of their 
scan, and smoked one of their own cigarettes to satiety (ad 
libitum) approximately 25 minutes before data acquis-
ition to minimize the influence of smoking on vasculature 
[38], which affects blood flow in the brain. Baclofen has a 
short half-life (approximately 4 hours), thus participants 
took their medication (20 mg baclofen or matching place-
bo) 1−1.5 hours prior to the T2 session in the presence of 
study staff to ensure medication compliance and stand-
ardize dose time. To minimize “carryover” effects in neu-
ral response to SCs, non-SCs were presented before SCs 
[39]. While it is customary in some paradigms to counter-
balance stimuli across scans and across participants to 
minimize a confounding effect of stimulus order in the re-
sults, we have previously established that (1) order effects 
are negligible [9], and (2) such counterbalancing can in-
troduce a “carryover” effect in responses, as craving eli-
cited by SCs, when presented first, are not completely ex-
tinguished by the time non-SCs are subsequently pre-
sented [39]. Participants completed the Craving and 
Withdrawal Questionnaire (CWQ) to assess SC-elicited 
changes in craving and withdrawal before and immedi-
ately after the SC task [9,40]. 
fMRI Stimuli 
Stimuli presented during the non-SC and SC scans com-
prised audiovisual clips, each nine minutes long, featur-
ing actors differing in race, age, and sex, and either smok-
ing-related or nonsmoking-related cues. Unlike BOLD 
fMRI, perfusion MRI provides an objective measurement 
of blood flow, which precludes the need for counter-
balancing. As such, the non-SC video was presented be-
fore the SC video, to prevent carryover effects. To prevent 
practice effects, participants saw one of two similarly va-
lanced SC and non-SC videos at their first scan, and the 
second set of videos at their second scan. The order of 
presentation of videos was pseudorandomized across 
subjects. The SC videos featured actors smoking, while 
using language explicitly designed to induce desire for a 
cigarette (e.g., “The cigarette I enjoy most is the first ciga-
rette of the day”). The non-SC videos featured actors, but 
they were not smoking, and instead, told short stories un-
related to smoking and without smoking reminders. 
During the SC videos, subjects held one of their own ciga-
rettes in their preferred hand, and a match was lit and ex-
tinguished, providing visual and olfactory stimuli to en-
hance neurophysiological and subjective cue reactivity. 
During the non-SC video, subjects held a freshly sharp-
ened pencil. 
Scan Protocol and Parameters
MRI scanning occurred on a Siemens 3.0 Tesla Trio 
whole-body scanner (Siemens AG, Erlangen, Germany), 
using a standard Transmit/Receive head coil. High reso-
lution MR images were acquired using T1-weighted 3D 
magnetization-prepared rapid gradient echo (MPRAGE) 
scan (TR/TE/TI = 1,620/3/950 ms, flip angle = 90°, band-
width = 150, voxel size = 1 mm3, matrix = 192 × 256, sli-
ces = 160). Two-dimensional pCASL perfusion fMRI was 
used to acquire resting baseline, SC, and non-SC scans. 
The resting scan protocol included 45 resting label/con-
trol image pairs (labeling time, 1.5 seconds; post-labeling 
delay, 1,000 ms; matrix, 64 × 64 × 18; flip angle, 90°; TR, 
3.5 seconds; TE, 17 ms; slice thickness, 7.2 mm; voxel 
size = 3.44 × 3.44 × 7.2 mm). The SC and non-SC scan 
protocols each included 68 cue label/control image pairs 
(labeling time, 1.5 seconds; post-labeling delay, 1,500 ms; 
matrix, 64 × 64 × 18; flip angle, 90°; TR, 4 s; TE, 17 ms; 
slice thickness, 7.2 mm; voxel size = 3.44 × 3.44 × 7.2 mm).
Imaging Data Preprocessing
We performed image processing using Statistical Para-
metric Mapping 12 (SPM12, the FIL Methods Group, 2016), 
ASL toolbox [41], Functional MRI of the Brain Software 
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Library [42] and custom scripts in MATLAB 2016a [43]. 
Prior to the analyses, brain images were visually in-
spected for gross movement, structural abnormalities and 
whole brain coverage. Each participant’s anatomical and 
ASL images were manually reoriented to the anterior/pos-
terior commissure line (AC-PC line), to improve segmen-
tation and normalization accuracy. The raw echoplanar 
imaging images were then realigned to correct for head 
motion using the method proposed by Wang [44]. The 
mean ASL image was aligned to the anatomical image of 
each subject using the FSL Boundary Based Registration 
(BBR) approach [45]. Using SPM, the anatomical image of 
each subject was probabilistically segmented into grey 
matter, white matter and cerebrospinal fluid to construct a 
binary brain mask [46]. The brain mask was down-sam-
pled to the MNI space using the BBR co-registration pa-
rameters, and was used to restrict the CBF computation 
within the mask. Thereafter, a CBF time series was ob-
tained by pairwise control-label subtraction, normalizing 
by corresponding control image, and using a single com-
partment model with recommended parameters [47]. 
Image Quality Control Assessment 
A mean CBF map was obtained using a Structural 
Correlation with Robust Bayesian (SCRUB) estimation ap-
proach [48,49] to remove artifacts from ASL-CBF images. 
The quality of mean CBF maps for each subject was eval-
uated using an automated quality evaluation index (QEI) 
[50], with output values between 0 (no signal) and 1 
(highest signal). A QEI of 0.7 or above demonstrates high 
sensitivity-specificity, and thus was our criterion for in-
clusion in analyses. The anatomical images were normal-
ized to the MNI space using FSL non-linear registration 
and this, coupled with the BBR transformation, was used 
to normalize the CBF maps to the MNI space. The normal-
ized CBF maps were thereafter smoothed with a 5mm full 
width at half maximum Gaussian kernel. For group level 
analyses, each model included a global calculation of the 
mean voxel value within the image as a regressor of no in-
terest for data normalization.
Demographics and Behavior Analyses
We conducted all demographics and behavior analyses 
in R version 3.4.2 (https://www.r-project.org/) [51]. Before, 
and immediately after viewing SCs, participants were ver-
bally administered the CWQ, which included a question 
to probe craving: “On a scale of 1−7, with 7 as the high-
est and 1 as the lowest rating, how much do you crave a 
cigarette right now?” We calculated a change score for 
subjective craving (post-SC−pre-SC) such that a positive 
score indicates an increase in craving. We analyzed par-
ticipants’ responses using linear mixed models, in which 
subjective craving rating was the dependent variable, and 
group (BAC or PBO), timepoint (T1 or T2), and rating time 
(pre- or post-SC exposure) were included as fixed inde-
pendent variables [52]. We included participant ID as a 
random variable to provide each individual’s intercept. 
The primary result of interest was a group-by-week-by- 
pre-/post-cue exposure interaction. We also examined 
each group separately via post-hoc paired t tests to de-
termine potential differences between T1 and T2 SC-eli-
cited craving. 
Imaging Analyses
As in our previous work, all analyses included partic-
ipants’ sex and age as nuisance covariates. No other dem-
ographic or smoking characteristics were included in the 
model as there were no differences between groups in any 
relevant variables (Table 1). All results reported in a priori 
regions of interest (ROIs) were small-volume corrected 
(SVC) with a 5 mm radius around the previously identified 
clusters [9,25] and passed family-wise-error (FWE) cor-
rection, as well as a Šidák correction for multiple compar-
isons [53,54] at a statistical threshold of p ＜ 0.01. We 
used R and MANGO (http://ric.uthscsa.edu/mango/man-
go.html) [55] to generate figures. 
For hypothesis 1, that baclofen would increase CBF in 
cognitive control regions at rest, all participant’s mean 
resting images were included in a full factorial analysis, to 
determine a group-by-timepoint interaction. Based on the 
literature, ROIs for examining the effects of baclofen on 
the resting brain were the ACC (−8, −14, 40) and right 
and left dlPFC (±51, 24, 33) [12,24,25]. 
For hypothesis 2, that the baclofen-induced increase in 
ROIs at rest would be associated with a decrease in the re-
ward response during SC-exposure, we calculated a 
change value from the resting data (T2-T1) in the ROIs and 
entered them independently as covariates in the SC-mod-
el at T2, as previously described [26]. Based on the liter-
ature and our significant experience examining the brain 
substrates of SC-induced brain activity, ROIs included the 
VS, vmPFC, and avInsula [9,24,29,56,57]. 
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Fig. 3. The effects of baclofen on 
dorsolateral prefrontal cortex (dlPFC)
in the Brain at Rest Predict responses 
to smoking cues (SCs). (A) Coronal, 
axial, sagittal, and 3D images showing
a baclofen-induced increase in right 
dlPFC cerebral blood flow (CBF) in 
the brain at rest, Z = 2.95, p = 0.021. 
(B) The dlPFC increase in the brain at 
rest predicted a decrease in the neural
response to SCs in the ventral medial 
prefrontal cortex, Z = 4.33, pFWEcorr = 
0.002 (top 3D image) and the left 
ventral anterior insula, Z = 3.85, 
pFWEcorr = 0.002 (bottom 3D image). 
Coordinates are in MNI space. Clusters
are defined via whole-brain voxel- 
wise analysis. Values are family-wise
error (FWE) corrected. 
Fig. 2. Smoking cue-elicited craving before and after 3-weeks of 
medication. Participants were asked how much they craved a cigarette
before and after seeing smoking cues. Smoking cue-induced craving 
scores were calculated by subtracting pre-session ratings from post- 
smoking cue (SC) ratings at each timepoint. Baclofen, but not placebo 
participants reduce SC-elicited craving from pretreatment (T1) to 
during treatment (T2). Translucent bars indicate 95% confidence 
intervals.
RESULTS
Participant Characteristics
There were no differences in age, sex, race, ethnicity, 
education, IQ, FTND scores, CPD, pack years, or canna-
bis and alcohol use between BAC and PBO recipients 
(Table 1). A linear mixed model revealed an overall effect 
of CPD between the groups and timepoints, F(3,81) = 
3.05, p = 0.033. However, there were no effects of time-
point  = −1.57, standard error (SE) = 1.78, p = 0.38, 
group  = 2.20, SE = 3.95, p = 0.58, or the interaction be-
tween group and timepoint,  = −2.77, SE = 2.50, p = 
0.27. 
Adverse Events 
There were no differences between BAC and PBO 
groups in total number of adverse events t(33) = 1.56, p = 
0.13, d = 0.48. Because sedation, or “drowsiness,” is the 
adverse effect most commonly associated with baclofen, 
we examined it separately. There was no difference be-
tween groups in sedation, t(36) = 1.32, p = 0.20, d = 0.42.
Smoking Cue-elicited Craving 
Two participants’ SC-elicited craving data were missing. 
Of the remaining participants, a linear mixed model re-
vealed an overall effect, F(3,78) = 2.95, p = 0.038. There 
was an effect of timepoint,  = −1.32, SE = 0.49, p ＜ 
0.01, no effect of group,  = −1.59, SE = 1.07, p = 0.14, 
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Fig. 4. Baclofen’s effects on brain response to SCs trends toward correlation with SC-elicited craving. (A) The magnitude of decrease in SC-induced 
craving (T2-T1) trended toward correlation with the magnitude of decrease in left avInsula activation (T2-T1), MNI coordinates (−38, 14, −16), r =
0.36, p = 0.06, as well as (B) the magnitude of decrease in the vmPFC, MNI coordinates (4, 22, −14), r = 0.35, p = 0.07. 
SC, smoking cue; T1, before baclofen; T2, during treatment with baclofen; avInsula, anterior ventral insula; vmPFC, ventromedial prefrontal cortex.
and an interaction effect between timepoint and group  = 
1.36, SE = 0.68, p = 0.047. Post-hoc t tests revealed that 
this effect was driven by a reduction in SC-elicited craving 
in baclofen participants from T1 to T2, t = 2.90, p ＜ 0.01 
(Fig. 2), whereas there was no change in placebo partic-
ipants between timepoints, t = −0.09, p = 0.93.
Imaging Results
All imaging results can be viewed in detail at 
ArielKetcherside.com. For our first hypothesis, that baclo-
fen would increase resting brain activity in cognitive con-
trol regions, we performed a full factorial model in 
SPM12. This showed a timepoint-by-group interaction 
such that BAC participants had greater resting activation 
in the right dlPFC at T2 and compared to PBO (Z = 2.78, 
SVC p FWEcorr = 0.03, Fig. 3A, see S1 for boxplot). There 
was no effect of timepoint on resting state CBF in our other 
ROIs, the ACC or the left dlPFC in BAC. 
Given our second hypothesis, that baclofen-induced 
change in CBF within our ROIs at rest would associate 
with a decrease in the reward response during SC ex-
posure, we extracted the values from the ROI wherein we 
saw an effect, the right dlPFC (calculated as T2-T1) and 
used them as covariates in the SC T2 model, as previously 
described [26]. We found that the baclofen-induced in-
crease in right dlPFC at rest was associated with a de-
crease in neural response in the vmPFC (Z = 4.33, pFWEcorr = 
0.002) and left avInsula (Z = 3.85, SVC p FWEcorr = 0.002) 
during SC exposure (Fig. 3B). 
Post-hoc Brain-behavior Correlations 
We performed a post-hoc analysis to determine if ba-
clofen-induced changes in neural response to SCs corre-
lated with subjective reports of SC-induced craving. First, 
we performed a full factorial analysis to identify a stimulus 
(SCs and non-SCs)-by-timepoint (T1 and T2) interaction 
effect on neural changes in SC response during treatment 
in both the baclofen and placebo groups. We then ex-
tracted the average value from a 5 mm sphere surround-
ing the peak voxel of the SC ROIs and examined whether 
these values correlated with the magnitude of change in 
SC-induced ratings for craving from T1 to T2. We ob-
served a trend toward correlation between the magnitude 
of the decrease in SC-craving and the magnitude of the 
decrease in the left avInsula from T1 to T2 (−38, 14, −16), 
r = 0.36, p = 0.06 and in the vmPFC (4, 22, −14), r = 0.35, 
p = 0.07, the two regions previously identified in our test-
ing of hypothesis 2. While these do not pass the 
“bright-line fallacy” threshold of significance [58], or the 
Šidák correction for multiple comparisons that would be 
most prudent for interpretation as stand-alone results 
(p adjusted ＜ 0.03) [53,54,59], we present them here for in-
terpretation in the context of our overall results. While fur-
ther examination is necessary, these preliminary findings 
suggest that, the more BAC participants exhibited reduced 
activation in limbic regions, which have been shown 
throughout the literature to be associated with craving, 
the less SC-craving they reported (Fig. 4). The same analy-
sis in PBO participants showed no correlations. 
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Additional post-hoc analyses on this data set are pro-
vided at ArielKetcherside.com.
DISCUSSION
We examined baclofen’s effects on the resting brain in 
a priori cognitive control regions (ACC and dlPFC) and re-
lationships between baclofen-induced resting changes 
and response to SCs in reward regions (vmPFC, VS, 
avInsula). Results indicate that baclofen increased resting 
right dlPFC activation, which was associated with a de-
crease in left avInsula and vmPFC SC-elicited activation. 
Further, while both groups reported SC-elicited craving 
prior to medication (T1), only baclofen-treated subjects 
showed reduced SC-elicited craving during treatment 
(T2). Our findings align well with those of Holla and col-
leagues [24] who showed that baclofen increased activity 
in the dlPFC and decreased activity in the insula in AUD 
patients during alcohol cue exposure that subsequently 
predicted time to relapse, suggesting a common mecha-
nism for mitigating craving across substances of abuse.
Our finding that baclofen increased dlPFC activation at 
rest replicates our previous findings [25] and is consistent 
with literature implicating the dlPFC in recovery from sub-
stance use disorders [24,60-62]. The prevailing theory 
uniting these studies postulates that increased resting ac-
tivity in the dlPFC can improve individuals’ ability to miti-
gate conditioned responses that lead to relapse. The 
dlPFC is a hub of inhibitory control within the executive 
control network [63], and during SC-reactivity, it in-
tegrates cue perception, craving, and behavior planning 
to seek or avoid SCs [64]. Thus, the baclofen-induced in-
crease in resting dlPFC observed here could indicate a 
similar increase in tonic executive control, enabling par-
ticipants to self-regulate reactivity to SCs. 
When included as a covariate in the model assessing 
SC-reactivity, the BAC-induced increase in resting dlPFC 
activation predicted a decrease in left avInsula activity in 
response to SCs, indicating that, the greater the tonic 
dlPFC activation, the less the avInsula responded to SCs. 
The insula integrates sensory, salience, and executive 
control networks, and the avInsula is associated with sub-
jective “urge” for drugs in response to drug cues 
[9,29,64-68]. Janes et al. have shown that avInsula activa-
tion in response to SCs predicted relapse during sub-
sequent smoking cessation attempts [11,12] and that de-
creased anterior insula-dlPFC functional connectivity dur-
ing SC exposure predicts relapse [12]. In line with this 
work, our findings suggest that the greater the tonic activa-
tion of the dlPFC, the less the avInsula responds to SCs, 
which could potentially prevent relapse. Associations be-
tween the left avInsula and craving have been observed 
repeatedly in the SC literature, however the right insula 
has also been implicated, and thus the laterality of our re-
sults should be addressed [11,12]. One such explanation 
lies in previous work suggesting that the left avInsula re-
sponds more to positive stimuli than the right [69]. As our 
SCs are highly appetitive, the left avInsula may have been 
more engaged during SC exposure prior to medication, 
such that baclofen’s effects are observable to a greater ex-
tent on the left side. Baclofen’s modulation of the dlPFC 
was also associated with a decrease in vmPFC response to 
SCs. This is congruent with literature showing that vmPFC 
activation during SC exposure is associated with craving, 
while its reduced activity is associated with smoking ces-
sation interventions and reduced craving [26,30,70]. 
Collectively, results suggest a mechanism by which ba-
clofen may blunt SC-responsivity, and thereby prevent 
SC-induced relapse.
Additionally, post-hoc analyses in baclofen participants 
showed that the magnitude of baclofen-induced de-
creases in neural response to SCs in the avInsula and 
vmPFC (T1-T2) trended toward correlation with the mag-
nitude of the decrease in subjective reports of SC-induced 
craving (T1-T2). In other words, the more BAC partic-
ipants exhibited reduced activation in limbic regions, 
which have been established within the literature as 
mechanisms of craving, the less SC-craving they reported. 
While these correlations were small and only trended to-
ward statistical significance, we note that patterns in the 
data are notable, given the small range of possible an-
swers to the craving questionnaire (1−7) and the ensuing 
double subtraction of the scores. Given that these results 
link our imaging and behavioral findings, they further sup-
port our hypothesis for the proposed mechanism of baclo-
fen in SC-craving reduction. Furthermore, they are similar 
to our previous results [26]. As such, this relationship 
should be examined further in future work with a more 
sensitive measurement.
We did not observe baclofen-induced increases in the 
left dlPFC at rest. Evidence for functional heterogeneity 
between the right and left dlPFC indicates the right is in-
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volved in hierarchical evaluation, while the left is in-
volved in the evaluation of possible outcomes [71]. Thus, 
tonic orientation toward identifying potentially relevant 
stimuli at rest [72], without the need to evaluate potential 
outcomes, may have engaged the right dlPFC in our study. 
Thus, lateralization should be examined in future work. 
Baclofen’s effects did not extend to the VS in the current 
study. This could be due to individual heterogeneity with-
in our sample, including sex and/or genetic differences 
[56,73], and the inclusion of non-SC vulnerable in-
dividuals, all of which we are underpowered to examine. 
These null findings underscore the heterogeneity in re-
sponse to baclofen, and the importance of differentiating 
SC-vulnerable individuals from other treatment seekers. 
To date, most studies of baclofen for SUDs are for AUD, 
with equivocal results [74-76], perhaps partially because 
potential heterogeneity in treatment response has not been 
examined. To date, three AUD studies have included neu-
roimaging during alcohol cue exposure [21,22,24], with 
modest samples and mixed findings, however, they all 
emphasize (1) that baclofen’s mechanism of action may 
be through blunting cue reactivity and that (2) more work 
is needed to understand this mechanism. Logge et al. par-
ticularly showed a dose-response effect such that a higher 
dose of baclofen (75 mg/day) reduced heavy drinking 
days compared to a lower dose (30 mg/day), which also 
warrants consideration in future studies. 
Additional smoking-cessation and relapse-prevention 
medications are necessary for smokers trying to quit, as 
the most commonly-prescribed agent, varenicline, does 
not help the majority of patients to whom it is prescribed 
[17,77]. Our group previously showed that the mechanism 
by which varenicline reduces SC-reactivity is through an 
increase in resting lateral OFC activation, which predicts 
a decrease in SC-response in the medial OFC and ventral 
striatum [26]. Contrasted with the regions affected by ba-
clofen in this study, this differential neural response to var-
enicline suggests that the medications have different 
mechanisms of action. Notably, baclofen, but not vareni-
cline patients show a reduction in avInsula response to 
smoking cues, and the avInsula is well-established hub of 
interoception and craving [11,66,68]. In this vein, one 
might speculate that varenicline’s limited effectiveness 
may be because it does not directly block SC-reactivity: in 
all previous varenicline studies examining SC-reactivity, 
participants continued to smoke during treatment, before 
assessment [26,78,79]. Perhaps the repeated blockade of 
nicotine reward while smoking extinguishes conditioned 
associations between the cues and cigarettes. Thus, as 
Brandon and colleagues explicitly suggest, the observed 
blockade of SC-induced craving could occur through 
temporary SC-reward extinction [78]. Thus, varenicline’s 
action to block reinforcement suggests it may be more 
helpful for abstinence initiation in those whose vulner-
abilities include avoidance of withdrawal and reward re-
inforcement [16], while baclofen may act as a relapse- 
prevention agent in a cue-vulnerable subgroup, abstinent 
at treatment initiation. This previously unaddressed em-
phasis on the potential use of baclofen for relapse-pre-
vention rather than abstinence-initiation could partially 
explain the discordant literature. As such, future studies 
may find it useful to design studies that explicitly test the 
usefulness of medications in abstinence-initiation and/or 
relapse prevention to address individual vulnerabilities. 
Baclofen has several inherent advantages for use as a 
medication for smoking cessation. It is currently approved 
for muscle spasticity by the United States Food and Drug 
Administration [80], has a history of safety, is not abused, 
and its generally benign adverse effects, when present, are 
well-documented [81]. It is available in generic form and 
is cost-effective. Its short half-life (4 hours) suits its use as a 
relapse prevention medication on an as-needed basis: as 
SCs are often context-dependent (e.g., being surrounded 
by smokers at an event), an individual could take baclofen 
prospectively, on an as-needed basis. Thus, baclofen is af-
fordable and carries minimal risk, with an acute mecha-
nism of action precluding the need for daily dosage. 
Although baclofen’s effectiveness as a smoking cessation 
aid was not tested here, it has shown promise in the few 
placebo-controlled studies that have tested it. In a para-
digm similar to the current study, using the same dose of 
baclofen and setting the Quit Date to occur after 3 weeks 
of study participation, baclofen reduced CPD [82]. In an-
other study conducted in alcohol dependent smokers 
seeking treatment for both, baclofen increased the num-
ber of days of abstinence of co-use [83]. While both of 
these preliminary studies show proof of concept for fur-
ther clinical examination in treatment-seeking cigarette 
smokers baclofen’s efficacy has been challenged [76]. An 
additional factor that may underlie the mixed therapeutic 
profile of baclofen is individual response to medication. 
While some studies show that low doses (~30 mg per day) 
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are effective other studies show a dose response effect 
with higher doses showing more effectiveness [22]. Marsot 
et al. [84] recently identified a potential mitigating factor 
that may provide some insight. In this pharmacokinetic 
study the plasma concentration of baclofen showed 
marked interpatient variability that remained unexplained 
by a multitude of potential confounding factors. 
Limitations and Future Directions
Although this study is strengthened by its within-subjects, 
placebo-controlled, longitudinal design, it has limitations. 
First, the modest sample size precludes our ability to ex-
amine heterogeneity in response to SCs or to baclofen that 
may be introduced by additional factors such as in-
dividual pharmacokinetics [84] that might be affected by 
sex, genetics, and hormonal variability [40,73]. Further, 
to heighten homogeneity in brain response, a particular 
design feature was to minimize changes in smoking be-
havior across participants; participants were asked to 
‘smoke as usual’ until after the on-medication testing day 
and smoked to satiety immediately before both test days, 
which precluded the ability to study its potential effective-
ness as a relapse prevention agent. Despite this, the liter-
ature to date indicates that baclofen does not block re-
inforcement while smoking, but rather influences reward 
circuitry [20,85]. Nonetheless future studies should ex-
amine baclofen’s ability to block SC-reactivity explicitly 
in abstinent smokers. 
Conclusions
To date, the majority of smokers remain unaided by first 
line available smoking cessation medications that act to 
mitigate withdrawal and block reinforcement. As SC re-
activity is a known relapse predictor, additional treatment 
strategies that specifically target SC reactivity are crucial. 
Our results suggest that the GABA-B agonist, baclofen, 
mitigates the enhanced reward response to SCs, and that 
this occurs through an increase in tonic activation of the 
dlPFC, an executive control region. This mechanism is 
congruent with the theory gaining recognition in the field, 
that strengthening tonic executive functioning facilitates 
recovery from SUDs. Finally, the variable effectiveness of 
baclofen for SUDs documented to date may actually in-
dicate a difference in cue-vulnerability vs. reward-sensitivity 
in treatment-seeking individuals. Thus, baclofen may be 
most effective in facilitating relapse prevention in cue vul-
nerable smokers who have already quit. 
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